DiaSorin said it plans to acquire Luminex Corp. for $37 per share, or approximately $1.8 billion, in an all-cash transaction, according to a news release.
DiaSorin said the acquisition will provide it with access to multiplexing technology, where Luminex has more than 900 clients, and expand its presence in the United States.
“We are really excited about this transaction, which we believe creates value for our shareholders and represents an outstanding opportunity for our future growth, positioning DiaSorin and Luminex as a unique combination of diagnostics specialists,” said Carlo Rosa, CEO of DiaSorin Group.
Luminex will be merged with a newly formed U.S. subsidiary of DiaSorin. The transaction, which is being financed with a mix of cash and external financing, is expected to close within the third quarter of 2021.
